|
Synonyms: CAM-3001 | KPL-301
Compound class:
Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Phase 2 trial results from RA patients were published in 2018 [1] which showed that the effective response to mavrilimumab therapy was maintained long-term (at 122 weeks), and that it was well-tolerated. The development program on mavrilimumab in RA has since been discontinued, but development remains active in GCA. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Clinical candidate therapeutic for RA (Phase 2 studies completed). | |
| Temporal arteritis |
Disease Ontology:
DOID:13375 OMIM: 187360 Orphanet: ORPHA397 |
Mavrilimumab is a Phase 2 clinical candidate for temporal arteritis (giant cell arteritis). | |
